The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy

Olivry, Thierry; Sousa, Candace A.

doi:10.1016/s0165-2427(01)00314-2

Cited by 47 publications

(54 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glucocorticoids are the most commonly used drugs for treating a variety of inflammatory skin diseases including CAD [28]. However, the adverse effects of glucocorticoids such as skin atrophy and iatrogenic Cushing's syndrome has limited the use of these compounds [2].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis

et al. 2012

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effects of a topical spray containing 0.0584% hydrocortisone aceponate (HCA) on canine atopic dermatitis (CAD) and to evaluate the skin barrier function during the treatment of CAD. Twenty-one dogs that fulfilled the diagnostic criteria for CAD were included in this study. The HCA spray was applied once a day to the lesions of all dogs for 7 or 14 days. Clinical assessment was performed before (day 0) and after treatment (day 14), and clinical responses were correlated with changes in skin barrier function. CAD severity significantly decreased after 14 days of HCA treatment based on the lesion scores (p ＜ 0.0001), which were determined using the CAD extent and severity index (CADESI-03) and pruritus scores (p ＜ 0.0001) calculated using a pruritus visual analog scale. Transepidermal water loss, a biomarker of skin barrier function, was significantly reduced compared to baseline (day 0) measurements (p ＝ 0.0011). HCA spray was shown to be effective for significantly improving the condition of dogs suffering from CAD. This treatment also significantly improved cutaneous hydration and skin barrier function in the animals.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The complex aetiopathogenesis of CAD is reflected in the individually tailored, combination therapeutic treatments often required for its effective management (Nuttall 2008). Strategies commonly employed include: allergen avoidance; allergen-specific immunotherapy ; antihistamine pharmacotherapy (DeBoer and ; antimicrobial therapy for secondary infections; essential fatty acids ; glucorticoid pharmacotherapy (Olivry and Sousa 2001a); and nonsteroidal antiinflammatory pharmacotherapy including immunosuppressive drugs (Marsella and Olivry 2001). Of these, glucorticoid steroids (GC) and cyclosporin A (CsA) were the most effective drugs available for the treatment of CAD (Olivry and Sousa 2001b).…”

Section: Introductionmentioning

confidence: 99%

“…This criterion further complicates the process for determining an optimal treatment regimen. For example, GC is associated with numerous detrimental side effects with the risk that its benefits may be outweighed by potential complications (Nuttall 2008;Olivry and Sousa 2001a). This is especially true for long-term treatment regimes.…”

Section: Introductionmentioning

confidence: 99%

Masitinib for the treatment of canine atopic dermatitis: a pilot study

Daigle¹,

Moussy

Mansfield

et al. 2009

Vet Res Commun

View full text Add to dashboard Cite

There is an on-going need to identify medications suitable for the long-term treatment of canine atopic dermatitis (CAD). Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor. A strong relationship exists between the SCF/c-KIT pathway and pathogenesis of CAD, suggesting that masitinib may potentially fulfil the above role. This study reports on an uncontrolled pilot study of masitinib in CAD. Masitinib was administered orally to 11 dogs at a mean dose of 11.0 +/- 1.83 mg/kg/day (free base) for 28 days. Treatment response was assessed by evolution of clinical appearance according to a modified version of the Canine Atopic Dermatitis Extent and Severity Index (mCADESI), pruritus scale and surface area of lesions. Masitinib improved CAD with a mean reduction in mCADESI of 50.7 +/- 29.8% (95% C.I. = 29.4-72.0; p = 0.0004) at day 28 relative to baseline, with 8/10, 8/10 and 4/10 dogs showing improvement of >or=33%, >or=40% and >or=50%, respectively. Improvement was further evidenced by a decrease in pruritus score and the surface area of lesions. No serious or severe adverse events occurred during this trial, although 6/11 dogs presented with mild to moderate treatment related adverse events. There is sufficient compelling evidence to warrant further investigation.

show abstract

“…Moreover, in dogs, current therapy commonly involves allergen-specific immunotherapy (Griffin and Hillier 2001) or symptomatic treatment with either corticosteroids (Olivry and Sousa 2001) or cyclosporin A (Olivry et al 2002). Neither one of these therapies is guaranteed successful or without side effects.…”

Section: Introductionmentioning

confidence: 99%

Intradermal injection of Hsp60 induces cytokine responses in canine atopic and healthy skin

Lee

Rutten

Kooten

et al. 2008

Cell Stress and Chaperones

View full text Add to dashboard Cite

The purpose of this study was to investigate the immunoregulatory potential of Hsp60 in the skin of dogs with atopic dermatitis. Three dogs with chronic atopic dermatitis and four healthy dogs were injected intradermally with Hsp60 and phosphate-buffered saline. Biopsies were taken before testing from non-injected control skin, lesional and non-lesional atopic skin, and 48 and 72 h after injection. Analysis of cytokine messenger RNA was performed using quantitative real-time polymerase chain reaction. Forty-eight hours after Hsp60 injection, a rise in interleukin (IL)-10 was found (P=0.034) with the highest expression levels in non-lesional atopic and control skin. A rise of transforming growth factor beta (P=0.015) and IL12p40 (P=0.017) was noticed 72 h after Hsp60 injection in control skin. No significant differences were observed for the expression of IL-4, IL-12p35, and interferon gamma. The results indicate that Hsp60 is able to induce cytokines of a regulatory and Th1 phenotype in the skin. Furthermore, this study seems to provide a first indication of deficient Hsp60 response in atopic dermatitis affected skin.

show abstract

The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy

Cited by 47 publications

References 15 publications

Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis

Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis

Masitinib for the treatment of canine atopic dermatitis: a pilot study

Intradermal injection of Hsp60 induces cytokine responses in canine atopic and healthy skin

Contact Info

Product

Resources

About